In this week’s edition of InnovationRx, Recursion, a leading biotech company, has announced the launch of a new pre-seed venture fund through its biotech accelerator Altitude Lab. This fund aims to support early-stage biotech startups by providing up to $250,000 in capital, 12 months of lab space, and access to the accelerator program. The move comes in response to the challenges faced by biotech startups due to the uncertainty surrounding federal funding and grant cuts under the Trump Administration.
Recursion CEO, Chris Gibson, expressed his commitment to bridging the funding gap for biotech startups in a recent article published in Stat. He emphasized the importance of sustaining biotech innovation during these uncertain times and highlighted the need for collaboration within the industry.
In other news, the Trump Administration has announced a shift in strategy to control the spread of avian flu, moving towards stronger containment measures and vaccinations for poultry. The Department of Agriculture has granted a conditional license to Zoetis for a flu vaccine that can be administered to poultry, with plans to conduct field studies for avian flu vaccines in dairy cattle. This shift aims to reduce the transmission of the virus to humans, particularly farm workers involved in culling operations.
On the regulatory front, the FDA has approved GSK’s new vaccine against invasive meningococcal disease, targeting all five major types of bacteria that cause the disease. The vaccine showed a strong safety profile and immune response in a clinical trial of over 4,800 people aged 10 to 25 years.
In the realm of digital health and AI, Nvidia has unveiled Evo 2, an AI model developed in collaboration with researchers from Arc Institute and several universities. The model, trained on the DNA of over 100,000 species, aims to help researchers better understand genetic patterns across species and design genomes for bacteria. Nvidia has made Evo 2 available to scientists on its life sciences research platform BioNeMo.
In the field of medtech, iRhythm Technologies, known for its wearable heart monitor, is exploring new applications for its technology in detecting diseases beyond arrhythmias. CEO Quentin Blackford revealed plans to seek approval for monitoring sleep apnea and investigate the intersection of arrhythmias with other diseases to prevent heart attacks and strokes.
In public health news, the CDC’s advisory board has raised concerns about widespread cuts to public health agencies, citing the potential risks posed by global health threats such as Ebola, influenza, and avian flu. The board criticized the firing of experts in the midst of these challenges and urged for greater support for public health initiatives.
Overall, the biotech industry continues to navigate challenges and opportunities in the current landscape, with companies like Recursion and iRhythm Technologies leading the way in innovation and collaboration. Stay tuned for more updates on the latest developments in biotech, pharma, digital health, and medtech.
